AR129979A1 - Compuestos cíclicos y métodos de uso de estos - Google Patents
Compuestos cíclicos y métodos de uso de estosInfo
- Publication number
- AR129979A1 AR129979A1 ARP230101908A ARP230101908A AR129979A1 AR 129979 A1 AR129979 A1 AR 129979A1 AR P230101908 A ARP230101908 A AR P230101908A AR P230101908 A ARP230101908 A AR P230101908A AR 129979 A1 AR129979 A1 AR 129979A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- cyclic compounds
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un compuesto de la fórmula (1), o una sal aceptable desde el punto de vista farmacéutico de este. Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 39, o una sal aceptable desde el punto de vista farmacéutico de este, en combinación con uno o más excipientes aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263391548P | 2022-07-22 | 2022-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129979A1 true AR129979A1 (es) | 2024-10-16 |
Family
ID=89618536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101908A AR129979A1 (es) | 2022-07-22 | 2023-07-21 | Compuestos cíclicos y métodos de uso de estos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4558505A2 (es) |
| JP (1) | JP2025524002A (es) |
| KR (1) | KR20250039465A (es) |
| CN (1) | CN119923398A (es) |
| AR (1) | AR129979A1 (es) |
| AU (1) | AU2023312000A1 (es) |
| CA (1) | CA3262000A1 (es) |
| CL (1) | CL2025000161A1 (es) |
| IL (1) | IL318375A (es) |
| MX (1) | MX2025000635A (es) |
| TW (1) | TW202417445A (es) |
| WO (1) | WO2024020534A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117120442A (zh) * | 2021-01-26 | 2023-11-24 | 薛定谔公司 | 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物 |
| WO2025059027A1 (en) * | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1349834A2 (en) * | 2000-12-18 | 2003-10-08 | Eli Lilly And Company | Cycloalkyfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| US20240018157A1 (en) * | 2019-12-27 | 2024-01-18 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| EP4284804A1 (en) * | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
-
2023
- 2023-07-21 IL IL318375A patent/IL318375A/en unknown
- 2023-07-21 AU AU2023312000A patent/AU2023312000A1/en active Pending
- 2023-07-21 AR ARP230101908A patent/AR129979A1/es unknown
- 2023-07-21 WO PCT/US2023/070683 patent/WO2024020534A2/en not_active Ceased
- 2023-07-21 CN CN202380064528.2A patent/CN119923398A/zh active Pending
- 2023-07-21 JP JP2025503078A patent/JP2025524002A/ja active Pending
- 2023-07-21 CA CA3262000A patent/CA3262000A1/en active Pending
- 2023-07-21 TW TW112127390A patent/TW202417445A/zh unknown
- 2023-07-21 EP EP23843916.0A patent/EP4558505A2/en active Pending
- 2023-07-21 KR KR1020257005788A patent/KR20250039465A/ko active Pending
-
2025
- 2025-01-16 MX MX2025000635A patent/MX2025000635A/es unknown
- 2025-01-20 CL CL2025000161A patent/CL2025000161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3262000A1 (en) | 2024-01-25 |
| KR20250039465A (ko) | 2025-03-20 |
| CL2025000161A1 (es) | 2025-05-16 |
| TW202417445A (zh) | 2024-05-01 |
| WO2024020534A2 (en) | 2024-01-25 |
| CN119923398A (zh) | 2025-05-02 |
| EP4558505A2 (en) | 2025-05-28 |
| IL318375A (en) | 2025-03-01 |
| WO2024020534A3 (en) | 2024-03-07 |
| MX2025000635A (es) | 2025-04-02 |
| AU2023312000A1 (en) | 2025-02-20 |
| JP2025524002A (ja) | 2025-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129979A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| AR133027A1 (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| AR132338A1 (es) | Inhibidores de ras | |
| AR134265A1 (es) | Heterociclos y usos de los mismos | |
| AR133988A1 (es) | Inhibidores de ras-pi3k y usos de los mismos | |
| AR131906A1 (es) | Compuestos terapéuticos | |
| PE20251667A1 (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| CO2023016088A2 (es) | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 | |
| CO2023007882A2 (es) | Compuesto heterocíclico aromático, y composición farmacéutica y aplicación de estos | |
| AR128932A1 (es) | Inhibidores de bcl-xl | |
| DOP2023000221A (es) | Inhibidores heteroaromáticos bicíclicos de la klk5 | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| AR132166A1 (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| AR132905A1 (es) | Degradadores selectivos bifuncionales de smarca2 y sus usos terapéuticos | |
| PE13395A1 (es) | Composicion farmaceutica de imidazolil carbazolona | |
| AR124982A1 (es) | Macrociclos y sus usos | |
| AR125934A1 (es) | Compuestos macrocíclicos para tratar enfermedades | |
| AR130252A1 (es) | Inhibidores enzimáticos | |
| AR129570A1 (es) | Macrociclos que contienen indazol y su uso | |
| AR128896A1 (es) | Degradadores de ikzf2 y usos de estos | |
| AR133115A1 (es) | Inhibidores de kras | |
| AR129588A1 (es) | Inhibidores de kras | |
| AR134110A1 (es) | Inhibidores de ras | |
| AR126834A1 (es) | Profármacos y derivados de psilocina y usos de estos |